Table 2.
Cerebrospinal Measurements and RF Analysis*
| RF Analysis | |||||
|---|---|---|---|---|---|
| Control Group (n = 95) | AD Group (n = 48) | PD Group (n = 40) | Variable | MDA | |
| τ (pg/mL)†,‡,§ | 690.2 ± 39.1 | 1,425.0 ± 104.3 | 387.8 ± 46.9 | 1 | 2.27 |
| BDNF (pg/mL)†,‡ | 241.0 ± 3.7 | 202.3 ± 4.5 | 184.0 ± 5.5 | 2 | 1.94 |
| IL-8 (pg/mL)†,‡ | 16.4 ± 0.9 | 37.4 ± 3.5 | 36.3 ± 4.7 | 3 | 1.92 |
| Amyloid β42 (pg/mL)†,‡,§ | 371.8 ± 20.5 | 268.5 ± 27.1 | 510.6 ± 27.8 | 4 | 1.82 |
| β2-microglobulin (µg/mL)‡ | 1.1 ± 0.0 | 1.4 ± 0.1 | 1.6 ± 0.1 | 5 | 1.75 |
| VDBP (µg/mL)†,‡ | 0.6 ± 0.0 | 1.1 ± 0.1 | 1.2 ± 0.1 | 6 | 1.75 |
| ApoAII (µg/mL)†,‡ | 1.5 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.2 | 7 | 1.62 |
| ApoE (µg/mL)†,‡ | 3.9 ± 0.3 | 2.5 ± 0.2 | 2.3 ± 0.1 | 8 | 1.38 |
| Mean ± SD age (y)†,§ | 63 ± 12 | 70 ± 9 | 59 ± 10 | 9 | 1.08 |
| ApoAI (µg/mL) | 2.6 ± 0.1 | 2.3 ± 0.2 | 2.4 ± 0.3 | 10 | 0.81 |
| Haptoglobin (µg/mL) | 1.5 ± 0.2 | 2.3 ± 0.6 | 3.8 ± 1.1 | 11 | 0.39 |
| No. (%) female‖ | 51 (54) | 19 (40) | 9 (23) | 12 | 0.13 |
apo, apolipoprotein; BDNF, brain-derived neurotrophic factor; IL, interleukin; MDA, mean decreased accuracy; PD, Parkinson disease; RF, random forest; VDBP, vitamin D binding protein.
*
Data are given as mean ± SEM unless otherwise indicated. If nonparametric analysis of variance (Kruskal-Wallis test) resulted in P < .01, it was followed by Dunn corrected multiple comparisons with
†
P < .01 for control vs AD groups
‡
P < .01 for control vs PD groups
§
P < .01 for AD vs PD groups. Results from RF analysis are the ranking of variables from most to least contribution to separating groups, MDA in grouping when one variable was excluded from analysis.
‖
P < .01 by χ2 test.